Intensity Therapeutics (INTS) Cash & Equivalents (2023 - 2026)
Intensity Therapeutics' (INTS) quarterly Cash & Equivalents came in at $9.4 million in Q1 2026, up 909.47% YoY from $929000.0 in Q1 2025, and down 21.33% on a QoQ basis from $11.9 million in Q4 2025.
Intensity Therapeutics (INTS) Cash & Equivalents (2023 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 4 years of Cash & Equivalents data on file, last reported at $9.4 million in Q1 2026.
- Quarterly Cash & Equivalents rose 909.47% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 909.47% YoY) and the FY2025 annual result came in at $11.9 million, up 451.39% from the prior year.
- Cash & Equivalents eased to $9.4 million in Q1 2026, from $11.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $11.9 million in Q4 2025 to a low of $135765.0 in Q2 2023.
- A 4-year average of $5.4 million and a median of $6.7 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents surged 1967.54% — and 2025, when it plunged 87.54%.
- Tracing INTS's Cash & Equivalents over 4 years: stood at $8.6 million in 2023, then slumped by 74.73% to $2.2 million in 2024, then jumped by 451.39% to $11.9 million in 2025, then dropped by 21.33% to $9.4 million in 2026.
- The last three Cash & Equivalents figures came in at $9.4 million (Q1 2026), $11.9 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 9.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.53 Mn |
| Mar 31, 2026 | 9.38 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Sep 30, 2025 | 7.07 Mn |
| Jun 30, 2025 | 2.22 Mn |
| Mar 31, 2025 | 929,000.00 |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 7.46 Mn |
| Dec 31, 2023 | 8.56 Mn |
| Sep 30, 2023 | 6.69 Mn |
| Jun 30, 2023 | 135,765.00 |
| Mar 31, 2023 | 8.56 Mn |